Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer

Prostate

Volumn 66, Issue 4, 2006, Pages 439-444

  Kaku, Haruki ^a   Saika, Takashi ^a   Tsushima, Tomoyasu ^a   Ebara, Shin ^a   Senoh, Takashi ^a   Yamato, Toyoko ^a   Nasu, Yasutomo ^a   Kumon, Hiromi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Cessation of LH RH; Luteinizing hormone; Prostate cancer; Testosterone

Indexed keywords

CHLORMADINONE ACETATE; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; LUTEINIZING HORMONE; TESTOSTERONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FOLLOW UP; HUMAN; LONG TERM CARE; MALE; PRIORITY JOURNAL; PROSTATE CANCER; TIME; TREATMENT WITHDRAWAL;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; GONADOTROPIN-RELEASING HORMONE; HUMANS; LUTEINIZING HORMONE; MALE; MIDDLE AGED; PITUITARY GLAND; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; TESTIS; TESTOSTERONE;

EID: 33644780946     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20341     Document Type: Article

References (15)

1. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Gil T, Collette L, Pierart M. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295-300.
2. Soloway MS. Role of induction androgen deprivation before radical prostatectomy. Semin Urol 1995;13:142-147.
3. Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD, Akakura K. Intermittent androgen suppression in treatment of prostate cancer: A preliminary report. Urology 1995;45:839-844.
4. Szumacher E, Malone S, Huan S, Segal R. Intermittent androgen suppression in the management of prostate. Urology 1999;53:530-534.
5. Turkes A, Poeling WB, Grittiths K. The use of a depot LHRH analogue, Zoladex, in the treatment of prostatic cancer: A dose-interval study. Med Sci Res 1987;15:477.
6. Grant JB, Ahmed SR, Shalet SM, Costello CB, Howell A, Blacklock NJ. Testosterone and gonadotrophin profiles in patients on daily or monthly LHRH analogue ICI 118630 (Zoladex) compared with orchiectomy. Br J Urol 1986;58:539-544.
7. Nejat RJ, Rashid HH, Bagiella E, Katz AE, Benson MC. A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy. J Urol 2000;164:1891-1894.
8. Shahidi M, Norman AR, Gadd J, Huddart RA, Horwich A, Dearnaley DP. Recovery of serum testosterone, LH and FSH levels following neoadjuvant hormone cytoreduction and radical radiotherapy in localized prostate cancer. Clin Oncol 2001;13:291-295.
9. Oefelein MG. Serum testosterone-based luteinizing hormone-releasing hormone agonist redosing schedule for chronic androgen ablation: A phase I assessment. Urology 1999;54:694-699.
10. Kreis W, Budman DR, Delli Bovi P, Vinciguerra V. Rapid rise of serum testosterone following discontinuation of long term treatment of prostate carcinoma with an LHRH-agonist. Onkologie 1988;11:292-293.
11. Hall MC, Fritzsch RJ, Sagalowsky AI, Ahrens A, Petty B, Roehrborn CG. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. Urology 1999;53:898-902.
12. Miller LR, Partin AW, Chan DW, Bruzek DJ, Dobs AS, Epstein JI, Walsh PC. Influence of radical prostatectomy on serum hormone levels. J Urol 1998;160:449-453.
13. Smith JA Jr, Urry RL. Testicular histology after prolonged treatment with gonadotropin-releasing hormone analogue. J Urol 1985;133:612-614.
14. Giberti C, Barreca T, Martorana G, Truini M, Franceschini R, Rolandi E, Giuliani L. Hormonal pattern and testicular histology in patients with prostate cancer after long-time treatment with a gonadotropin-releasing hormone agonist analogue. Eur Urol 1988;15:125-127.
15. Huhtaniemi I, Nikula H, Parvinen M, Rannikko S. Histological and functional changes of the testis tissue during GnRH agonist treatment of prostate cancer. AM J Clin Oncol 1988; 11:S11-S15.